AstraZeneca Drug Reduces Chance of Death by Half in Some Lung Cancer Patients

AstraZeneca's Tagrisso cut the risk of death in half for patients with a mutation of the EGFR gene who had early stage lung cancer surgery.
Tagrisso is already approved to treat certain advanced non-small cell lung cancer patients with an EGFR mutation.
The trial confirms Tagrisso as the standard treatment for eligible patients with EGFR-mutated lung cancer.
Nearly 90% of patients on Tagrisso were alive after five years compared to 78% of those on a placebo.
AstraZeneca hopes these findings will help get Tagrisso to more patients who could benefit from it.